Article2007

The Selective Extrasynaptic GABAA Agonist, Gaboxadol, Improves Traditional Hypnotic Efficacy Measures and Enhances Slow Wave Activity in a Model of Transient Insomnia

James K. Walsh · Stephen Deacon · Derk‐Jan Dijk · Jonas Lundahl

91 citations0/0 files storedSLEEP

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Abstract

STUDY OBJECTIVES: Evaluate the hypnotic efficacy of gaboxadol, a selective extrasynaptic GABAA agonist (SEGA), in a phase advance model of transient insomnia. DESIGN: A randomized, double-blind, cross-over study in which habitual sleep time was advanced by 4 h. SETTING: Sleep research laboratories. PARTICIPANTS: 109 healthy subjects (18-58 y). INTERVENTIONS: Gaboxadol 5 mg, 10 mg, and 15 mg (GBX5, GBX10, GBX15) versus placebo (PBO). Zolpidem 10 mg (ZOL10) was used as an active reference. MEASUREMENTS: Polysomnographic (PSG) and self-reported (s) sleep measures RESULTS: Wakefulness after sleep onset (WASO) decreased (P < 0.05) and total sleep time (TST) increased (P < 0.001) in all treatments versus PBO. Latency to persistent sleep was shorter (P < 0.05) than PBO for all treatments except GBX5. GBX10 and GBX15 increased slow wave activity (SWA; 0.75-4.5 Hz, P < 0.001) and theta activity (4.75-7.75Hz; P < 0.001) and reduced sigma activity (12.25-15.0 Hz; significant for GBX15 only, P < 0.001) compared to PBO in NREM sleep EEG, in a dose-response manner. Zolpidem suppressed power density over a broad low frequency range including delta and theta frequencies (2.25-8.0 Hz, P < 0.05) and also enhanced sigma activity (P < 0.001). Self-reported sWASO and sTST improved for all treatments versus PBO (P < 0.05). Self-reported sleep latency was reduced following GBX10 (P < 0.05) and ZOL10 (P < 0.001). Neither drug treatment was associated with residual effects the morning after treatment. CONCLUSIONS: Gaboxadol and zolpidem improved objective and subjective efficacy measures in this model of transient insomnia. The gaboxadol-induced enhancement of SWA and theta activity and the reduction of sigma activity contrasts with zolpidem's effects on the spectral EEG. These differences may reflect the different mechanisms of action of the two drugs.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 91 citations exist upstream.

References

1989The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research 1968A manual for standardized terminology, techniques and scoring system for sleep stages in human subjects 1969A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects 2004Functional Neuroimaging Evidence for Hyperarousal in Insomnia 2001Beta/Gamma EEG Activity in Patients with Primary and Secondary Insomnia and Good Sleeper Controls 1986Ultrashort sleep-waking schedule. III. ‘Gates’ and ‘Forbidden zones’ for sleep 2002NREM Sleep EEG Frequency Spectral Correlates of Sleep Complaints in Primary Insomnia Subtypes 1979Successful Separation of Depressed, Normal, and Insomniac Subjects by EEG Sleep Data

Cited by

2009Enhancement of Slow Wave Sleep: Implications for Insomnia.2015Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people 2010Drug-Related Sleep Stage Changes: Functional Significance and Clinical Relevance 2007Evaluation of Automated and Semi-Automated Scoring of Polysomnographic Recordings from a Clinical Trial Using Zolpidem in the Treatment of Insomnia

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.